Agoracom Blog Home

Posts Tagged ‘small cap stocks’

POET $PTK.ca $POETF Announces Industry-First Flip-Chip DML Lasers

Posted by AGORACOM-JC at 8:16 AM on Thursday, December 17th, 2020

Enables the World’s Lowest-Cost and Smallest 100G CWDM4 Optical Engine

  • Completed and tested its high-speed Directly Modulated Laser (DML) designs using a distributed feedback (DFB) structure and successfully “flip-chipped” these lasers onto the Company’s Optical Interposer platform, which also incorporates several other industry-first accomplishments.
  • flip-chip assembly technique enables a true single-chip, fully integrated Optical Engine to be produced at wafer-scale, resulting in the lowest-cost, smallest-size 100G CWDM4 Optical Engine with a form factor of 9mm x 6mm, while including banks of four lasers, four monitor photodiodes, four high speed photodiodes, a multiplexer, demultiplexer, taps for power monitoring and features supporting a self-aligned fiber attach unit.

TORONTO, Dec. 17, 2020 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF) the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that it has completed and tested its high-speed Directly Modulated Laser (DML) designs using a distributed feedback (DFB) structure and successfully “flip-chipped” these lasers onto the Company’s Optical Interposer platform, which also incorporates several other industry-first accomplishments.

The flip-chip assembly technique enables a true single-chip, fully integrated Optical Engine to be produced at wafer-scale, resulting in the lowest-cost, smallest-size 100G CWDM4 Optical Engine with a form factor of 9mm x 6mm, while including banks of four lasers, four monitor photodiodes, four high speed photodiodes, a multiplexer, demultiplexer, taps for power monitoring and features supporting a self-aligned fiber attach unit.

“Without being able to flip-chip the lasers, we would be unable to assemble Optical Engines at wafer-scale, which is the single most important driver of cost. Wafer-scale processing enables the production of high unit volumes at low incremental costs, ultimately allowing us to reduce the cost of building photonics devices by 25% to 40% compared to conventional approaches,” stated Suresh Venkatesan, Chairman and CEO of POET. “Following our successful demonstration of this flip-chip assembly process, POET can now readily incorporate these lasers and other active devices into derivative optical engine configurations, supporting data communications applications such as 200G CWDM4, 100G CWDM6, and 100G LR4, telecom applications such as 5G, as well as other applications that could benefit from the small size and low cost of our platform technology.”

Four DML lasers are commonly used in 100G transceiver applications, a key initial target market for POET’s Optical Interposer, enabling high speed optical communication in the 2 to 10 km range. Operating at speeds of 25 gigabits per second (GPS), POET’s family of four DML lasers of different wavelengths are the first known commercial 25G DFB-type DML lasers to utilize a flip-chip process to passively align and bond to electronic and optical circuitry on the interposer platform, while maintaining optimal performance. Given the estimated total available market (TAM) for 100G transceivers of approximately $2.5 billion, POET believes that its recently formed JV company, SuperPhotonics Xiamen, can achieve annual revenue of over $100 million within this single market segment in the 2024-25 time frame.

Flip-chip assembly of electronic devices on circuit boards, MEMS (Microelectromechanical Systems) and other devices is an advanced manufacturing process for achieving electrical interconnect (often referred to as 2-D, 2.5-D and 3-D) in semiconductor architectures. To achieve the benefits of the planar architecture of POET’s Optical Interposer that facilitates wafer-scale processing, flip-chipping of lasers was an important development milestone, requiring POET to demonstrate that it could simultaneously optimize the RF (radio frequency) performance of the flip-chipped DML laser on interposer while preserving a low RIN (relative intensity noise) measurement both before and after assembly.   RF performance relates to the quality and power of the electrical signals, while RIN is a measure of stability of the lasers that are assembled on the Interposer.

“Beyond The Press Release”

POET Technologies goes “Beyond The Press Release” to discuss today’s news. Shareholders and other interested parties are encouraged to check back on this link before market open on the morning of Tuesday December 22, 2020.

https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/751215-poet-technologies-goes-beyond-the-press-release/messages/2293211#message

About POET Technologies Inc.
POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™ a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA and Singapore. More information may be obtained at www.poet-technologies.com .

Shareholder Contact for POET:
Shelton Group
Brett L. Perry
[email protected]
Company Contact for POET:
Thomas R. Mika, EVP & CFO
[email protected]

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, future growth, recruitment of personnel, opening of offices, the form and potential of its planned joint venture, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the failure of its products to meet performance requirements, operational risks in the completion of the Company’s anticipated projects, a delay or abandonment of its planned joint venture, delays in recruitment for its newly opened operations or changes in plans with respect to the development of the Company’s anticipated projects by third-parties, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075

CardioComm Solutions $EKG.ca to Bring #ECG Monitoring to Remote Patient and #COVID-19 Monitoring Platforms $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 8:38 PM on Tuesday, December 15th, 2020
  • Entered into a technology integration agreement with LiveCare Corp. and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med, to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform.
  • CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed.
  • Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service.
  • Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform’s remote patient monitoring teams.

TORONTO, ON / December 15, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) (“CardioComm” or the “Company“), a global provider of consumer heart monitoring and electrocardiogram (“ECG“) device and software solutions, is pleased to confirm it has entered into a technology integration agreement with LiveCare Corp. (“LiveCare“) and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med (“Alliance“), to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform.

CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed. Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service. Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform’s remote patient monitoring teams.

Link+ is a patented smart home gateway that integrates multiple key medical bio-sign monitoring devices in a patient’s home through a proprietary, touch-free device which is always connected to the 4G network. There is no need for patients to connect to any specific Wi-Fi network for the Link+ to fully operate and, once activated, the Link+ transmits data directly to LiveCare’s HIPAA compliant cloud. The Link+ is fully reimbursable through Medicare, Medicaid and many commercial insurance plans using multiple CPT codes.

Through the addition of the GEMS™ technology into the Link+ gateway device, the Link+ device will be capable of recognizing multiple ECG devices with up to 12 leads of ECG recording and provide Link+ customers with more options in choosing a device of their preference. The HeartCheck™ CardiBeat will be the recommended device for remote ECG patient monitoring given its availability in Canada, the US and Europe. All recorded ECGs will be passed through CardioComm’s SMART Monitoring ECG triaging service. ECG reports confirming the presence or absence of an arrhythmia will be provided to Link+ users.

The Link+ platform with ECG monitoring sales and marketing will be undertaken exclusively by Alliance with a focus on monitoring patients with or suspected to have COVID-19. Sales into the US is where the primary marketing efforts are targeted for 2021. CardioComm will see revenue from the sales of the HeartCheck™ CardiBeat ECG devices as well as from ECG triaging service fees.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

About LiveCare (www.livecareusa.com)

LiveCare’s mission is to improve patient outcomes, lower healthcare costs, and reduce hospital readmissions by developing technology to assist patients and providers during the critical transitional care period. LiveCare’s technology improves patient compliance with post-discharge medical protocols and enhances engagement between patients and providers. With a team of experienced professionals working in research and development, sales, and other capacities, LiveCare is putting the needs of patients and providers at the forefront as it moves the RPM market forward from its corporate headquarters in New York City.

About Alliance-Telemed, LLC

Alliance Tele-Med is a US-based Value-Added Wholesaler & Reseller of state-of-the-art remote patient monitoring (RPM) technology and care management services solutions for domestic and international healthcare delivery organizations and their patients. The company engages with healthcare and life sciences organizations such as Independent and Hospital-Owned Medical Practices, Independent Hospitals and Health Systems, Accountable Care Organizations (ACO’S), Independent Physician Associations (IPA’s), Provider Networks, large Employer Groups and Third Party Administrators, Clinics, FQHC and Regional Health Centers, Senior ‘Aging in Place’ Companies and Facilities such as Assisted Living Facilities, Nursing Homes, Skilled Nursing Facilities, Home Health Companies, pharmaceutical companies, and Clinical Research Organizations (CRO’s).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

KWESST $KWE.ca Extends Option to Acquire Non-Lethal Technology $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 7:47 AM on Tuesday, December 15th, 2020
  • Announced it has extended until January 15, 2021 its option to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology
  • The owner of the LEC Technology is DEFSEC Corporation (“DEFSEC”), an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST.
  • KWESST entered into a letter of intent with DEFSEC on June 6, 2020 to acquire the LEC Technology.
  • The parties continue to cooperate and are working toward a definitive agreement.

Ottawa, Ontario–(December 15, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced it has extended until January 15, 2021 its option to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology (“LEC Technology”).

The owner of the LEC Technology is DEFSEC Corporation (“DEFSEC”), an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST. KWESST entered into a letter of intent with DEFSEC on June 6, 2020 to acquire the LEC Technology. The parties continue to cooperate and are working toward a definitive agreement.

The LEC Technology is a proprietary non-lethal cartridge-based ordnance system with wide application in the rapidly growing market of soldier and law enforcement training, maintenance of public order, personal defence, and high-action gaming. “The market has long required a safer, lower-cost reliable alternative to existing solutions,” said Jeff MacLeod, KWESST Founder and CEO. “We see the LEC Technology as a strong fit with KWESST’s other smart ordnance technologies, like our Shot Counter system. Together, the LEC Technology and Shot Counter have the potential to anchor the build-out of a significant business unit specialized in smart ordnance systems, with a vast global market.”

The contemplated transaction would benefit from the deep combined experience of Jeff MacLeod and David Luxton in the specialty ordnance business. Mr. MacLeod is a highly knowledgeable defence industry executive with over 20 years’ experience in the field of small arms and advanced soldier systems. Prior to establishing KWESST, he was the General Manager of Colt Canada, the primary supplier of small arms to the Canadian military. David Luxton was the founder in 1990 of Simunition Inc., a business that develops and sells simulated munitions for realistic close quarters combat training for military and law enforcement around the world. He sold the business to a large military contractor and from 2015 – 2018 was the Executive Chairman of United Tactical Systems LLC, a U.S. company that develops and sells products for the global less-lethal market.

The purchase price for the LEC Technology shall be satisfied by the issuance to DEFSEC of 1,000,000 shares of KWESST and 500,000 share purchase warrants of KWESST at a price of $0.70 per share. The warrants shall vest as to 25% on the first anniversary of the closing of the LEC Technology acquisition and 25% on each of the subsequent three anniversaries of the completion of the LEC Technology acquisition. DEFSEC shall also be entitled to a 7% royalty on annual sales of the LEC Technology, net of taxes, duties, customs brokerage fees, shipping and handling costs, customer credits, discounts and returns, up to a cumulative maximum of $10 million. The other terms and conditions of the letter of intent between DEFSEC and KWESST are detailed on pages 16 and 17 of the Company’s Filing Statement dated September 28, 2020 which can be found at www.sedar.com. The acquisition of the LEC technology by KWESST remains subject to the approval of the TSX Venture Exchange.

The Company has granted to each of its three independent directors 250,000 stock options pursuant to the Company’s stock option plan. The stock options will vest over a two-year period and may be exercised at a closing price of the Company’s shares on the TSX Venture Exchange on December 15, 2020. The options will be outstanding for a period of five years from the date of grant. The Company has finalized the shares for debt described in its November 25, 2020 news release.

About KWESST

KWESST develops and commercializes high-value ultra-miniaturized technology applications that make a critical difference to the safety and operational effectiveness of personnel in the defence and security industries. The company’s current portfolio of unique proprietary offerings include: its signature TASCSTM (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons; the autonomous GreyGhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel; and, the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. All systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems including Frontline, Edge, Killswitch and ATAK (Android Tactical Assault Kit) among others. KWESST also has developmental “smart ordnance” projects including its “Shot Counter” system, which records the number and type of rounds fired, for optimized firearms maintenance and performance. The Company is headquartered in Ottawa, Canada, with representative offices in Washington, DC, London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.

Contact: Jason Frame, Investor Relations: [email protected]

For more information, please visit https://kwesst.com/

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the timing for the commencement of trading and the plans and operations of KWESST after giving effect to the Qualifying Transaction. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70231

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Enters into Distribution Agreement with Grande West to Offer BioCloud Technology Covid-19 Detection Systems for Vicinity Buses $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:26 AM on Tuesday, December 15th, 2020
kontrol-logo
  • Entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.
  • Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications.
  • Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada.

TORONTO, ON / December 15, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.

“We are pleased to enter into this agreement with Grande West as we continue to target the important sector of ground transportation with an established and successful bus OEM. We are excited to be working with another disruptive Canadian company, focusing on a transit solution that will make buses safer and reduce risk of potential viral spread for the riders,” stated Paul Ghezzi, CEO Kontrol Energy. “We anticipate that this additional partnership will add another channel for incremental sales as the need for safe detection of airborne viruses in public spaces grows.”

Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications. Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada. United States customers will be serviced by working with Kontrol Energy’s exclusive distributor, United Safety and Survivability Corporation. Pricing will not be disclosed for industry competitive purposes.

William Trainer, President & CEO of Grande West stated, “Grande West is proud to be partnering with Kontrol in working towards making our Vicinity buses safer for all of our end users. The Company is expanding its product lines into Electric Vehicles and lighter duty models and ramping up its U.S. sales and expects significant growth in the coming years. We will do everything we can to offer the safest and most effective transit solutions to our customers.”

As an initial step, Grande West is immediately ordering two of BioCloud units for its offices and operations headquarters in Aldergrove to improve the safety considerations of its employees.

About BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com

About Grande West Transportation Group

Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built VicinityTM medium and heavy-duty buses available in electric, CNG, gas and clean diesel drive systems. The Vicinity LightningTM EV with an electric propulsion drive system is available for 2021 deliveries.

The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West’s vehicles.

www.grandewest.com

www.vicinitybus.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloudTM (“BioCloud”) are subject to the risk that the Kontrol BioCloud may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

MedX Health Corp. $MDX.ca Announces the Rollout of DermSecure® in the Netherlands $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:13 PM on Monday, December 14th, 2020
Home - MedX Health

Highlights:

  • MedX partners with national telehealth leader IVPG in the Netherlands
  • Two skin screening clinics opened in November 2020, with more than 800 assessments on close to 500 patients completed to date using MedX’s DermSecure ® platform
  • Three additional clinics to come online in the Netherlands by the end of December 2020
  • IVPG plans to expand to 41 skin assessment clinics by 2022
  • More than half of all cancers reported in the Netherlands are skin cancers

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, announces that it has begun the rollout of DermSecure ® , MedX’s skin screening telemedicine platform, across the Netherlands in partnership with national telehealth leader The Netherlands Institute for Prevention and Health (“IVPG”).

“Telehealth allows us to assess patients, relay test results and provide video consultations with IVPG doctors, ultimately offering greater access to medical specialists during the COVID-19 crisis,” commented Paul Vlaanderen, IVPG Founder & CEO. “This improved access to healthcare specialists has directly resulted in higher quality care and the ability for patients to play a greater role in their healthcare management. We opened two locations in November and experienced substantial interest in the skin screening service, completing over 800 assessments on nearly 500 patients so far, and the DermSecure platform worked flawlessly. We will add another three locations, Rotterdam, Utrecht and Den Haag, to our IVPG network in 2020. IVPG further plans to bring the total number of scanning centers to 41 by 2022.”

“According to the World Cancer Research Fund, the Netherlands is ranked fifth globally for melanoma skin cancer. We know that early detection of skin cancer results in lower mortality rates, lower health care costs and much better patient outcomes. MedX’s advanced imaging technology and secure, scalable, teledermatology platform was a perfect fit to address the need for rapid skin screening in the Netherlands,” continued Mr. Vlaanderen.

Naman Demaghlatrous, MedX’s Managing Director, Europe, Middle East and Africa, was very impressed with the results of the implementation, stating, “Building on our pilot project with IVPG, DermSecure ® provides the requisite security and scalability to open multiple centers and expand this partnership significantly. We are honoured to work with Mr. Vlaanderen as he has been a pioneer in championing telehealth in the Netherlands. We look forward to playing a crucial role in enhancing Netherlanders’ access to early screening and thereby reduce skin cancer deaths.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com

About IVPG

IVPG is a Netherlands based Institute for Prevention and Health using telehealth for the delivery of digital healthcare. We are a collaboration of doctors and specialists. Together we help the Dutch to live a healthy and energetic life. IVPG provides the Dutch people with health information, free preventive examinations and advice to give more in-depth insight into their health. Although we are not always in control of our health, we can often manage it. That is our commitment. www.ivpg.nl

Forward-Looking Statements

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005867/en/

Investor Relations
Bill Mitoulas
[email protected]
Tel: +1.416.479.9547

VIDEO – Mountain Valley MD $MVMD.ca Catches Small Cap Fire After #Ivermectin Testimony In US Senate Called “Miraculous Effectiveness” In Prohibiting Transmission Of #COVID-19

Posted by AGORACOM-JC at 4:19 PM on Monday, December 14th, 2020

“It basically obliterates transmission of this virus”  

This was the testimony of  Pierre Kory, M.D., Associate Professor of Medicine at St. Luke’s Aurora Medical Center, delivers passionate testimony during the Senate Homeland Security and Governmental Affairs Committee hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.”

We interviewed Leigh Hughes, newly appointed Advisor to MVMD who will be supporting the Company in the areas of M&A, corporate finance and pharmaceutical licensing, to provide us with further insight as to why the testimony of Dr. Kory is so relevant to MVMD … and why Dr. Kory actually called MVMD last week to discuss the Company’s involvement with Ivermectin.

Mountain Valley MD has traded over 50,000,000 shares in the last 3 trading days, so there is a clear need for information amongst retail investors.

KWESST $KWE.ca Announces C$1.1 Million Follow-on Order For TASCS IFM From Key U.S. Military Customer $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 7:41 AM on Monday, December 14th, 2020
  • Announced a follow-on order for approximately C$ 1.1 million with a key U.S. military customer to expand use of the Company’s TASCS IFM system in military exercises, a key precursor to wider adoption
  • contract is for application of the TASCS IFM system on the 81mm mortar platform, which transforms it into a “smart” weapon system with greater accuracy and faster response time, improving soldier survivability and operational effectiveness.
  • Work under the order is scheduled to commence immediately.
  • Founder, President and CEO Jeff MacLeod commented that, “This marks another key validating milestone in a market where TASCS IFM on the 81mm mortar alone could ultimately be worth up to C$120 million in the U.S. and another C$400 million worldwide, given the large installed base of 81mm mortars in service with so many NATO and allied military forces.”

Ottawa, Ontario–(December 14, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced a follow-on order for approximately C$ 1.1 million with a key U.S. military customer to expand use of the Company’s TASCS IFM system in military exercises, a key precursor to wider adoption.

The contract is for application of the TASCS IFM system on the 81mm mortar platform, which transforms it into a “smart” weapon system with greater accuracy and faster response time, improving soldier survivability and operational effectiveness. Work under the order is scheduled to commence immediately.

KWESST Founder, President and CEO Jeff MacLeod commented that, “This marks another key validating milestone in a market where TASCS IFM on the 81mm mortar alone could ultimately be worth up to C$120 million in the U.S. and another C$400 million worldwide, given the large installed base of 81mm mortars in service with so many NATO and allied military forces.”

KWESST previously announced the completion of an earlier two-phase initial contract with the same customer that marked the introduction of TASCS IFM on 81mm mortars in military exercises. “It is very encouraging to see the accelerated pace at which this important customer is expanding the use of TASCS IFM in its field exercises, and their confidence in KWESST,” added MacLeod. “It is an honor to be working with them to enhance soldier survivability and effectiveness, which is our core mission.”

As previously announced, the TASCS IFM system has attracted interest from other NATO forces who have requested proposals from KWESST, which the Company is currently actioning. “The fact that the TASCS IFM confers so many modernization advantages without any modification to weapon platforms or munitions is a huge attraction,” said MacLeod.

He added that, “The 81mm mortar is just one of many different weapon platforms that can be transformed into a smart system with TASCS IFM, providing soldiers on the ground with real-time networked situational awareness and precision targeting information.” Accordingly, KWESST is pursuing additional global markets for the TASCS IFM, which can also work on platforms such as: 60mm mortars; grenade launchers; sniper rifles; drones; electronic decoys; and more, with a total addressable market of more than C$1 billion.

About KWESST

KWESST develops and commercializes high-value ultra-miniaturized technology applications that make a critical difference to the safety and operational effectiveness of personnel in the defence and security industries. The company’s current portfolio of unique proprietary offerings include: its signature TASCSTM (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons; the autonomous GreyGhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel; and, the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. All systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems including Frontline, Edge, Killswitch and ATAK (Android Tactical Assault Kit) among others. KWESST also has developmental “smart ordnance” projects including its “Shot Counter” system, which records the number and type of rounds fired, for optimized firearms maintenance and performance. The Company is headquartered in Ottawa, Canada, with representative offices in Washington, DC, London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.

Contact: Jason Frame, Investor Relations: [email protected]

For more information, please visit https://kwesst.com/

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the plans and operations of KWESST. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.



Image: TASCS IFM System on M252 (81mm)

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/7366/70148_ccd0de0d64153b68_001full.jpg

Empower Clinics $CBDT.ca $EPWCF Announces Receipt of Over $5,500,000 From Exercise of Warrants, Launches New Corporate Website for Future Integrated Healthcare $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:32 AM on Monday, December 14th, 2020
  • Announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020
  • The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company
  • It serves as an indication of the strength of Empower’s shareholder base and its following
  • Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond

VANCOUVER BC / December 14, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and validating novel COVID-19 testing protocols for CE, FDA and Health Canada approval is pleased to announce the following:

RECEIPT OF $5,500,000 + FROM THE EXERCISE OF WARRANTS ALLOWS EMPOWER TO CONTINUE TO EXECUTE WITH INCREASED STRENGTH

Empower is pleased to announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020. The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company. It serves as an indication of the strength of Empower’s shareholder base and its following.

The Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it has the war chest necessary to pursue numerous opportunities. KAI medical laboratory continues to expand nationwide in the U.S., Empower is growing physician services and direct access to patients through new clinics expansions and the company will provide dynamic technology-based healthcare services to meet patient needs.

Steven McAuley, Chairman and CEO of Empower stated, “The timing of these warrant exercises could not be better as we head into our biggest growth phase ever, thanks to rapidly growing demand for our KAI Medical Lab COVID-19 testing solutions, as well as, the impending launch of our FDA approved KAI Saliva Test plus the pending clinic group acquisition in Canada. These proceeds significantly bolster our financial strength, resources and confidence necessary to aggressively pursue our growth strategies in 2021.”

EMPOWER LAUNCHES NEW WEBSITE TO BETTER REFLECT COMPANY’S 2021 DIRECTION

The Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond, as well as, our defined vision as follows:

GROWTH PILLARS

Health & Wellness Is Our Purpose – Through our clinics in the US and telemedicine platform, our physicians treat patients in Oregon, Arizona and Washington State. Within this section you can read our statements about integrated care and patient first care.

Diagnostics & Tech Is Our Vision – The October 5th acquisition of Texas-based KAI Medical Laboratory was a significant achievement for Empower, as it firmly and immediately established the science and research side of Empower. In its first month, KAI delivered record revenues and soon after announced its first $1,000,000 COVID-19 testing contract for a major film and television studio.

This section is rich in information for investors that want to better familiarize themselves with the capabilities of KAI Laboratory and COVID-19 testing capabilities that attracted major contracts and R&D initiatives.

We invite all of our shareholders and prospective investors to visit our new website at https://www.empowerclinics.com/

EMPOWER TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM

The Company is commencing discussions on its “CEO Verified Forum” on AGORACOM, which is intended to serve as one of the Company’s social media platforms for interaction with current and prospective shareholders.

Steven McAuley added “The growth experienced by Empower over the past 12 months has come from all sources providing the best possible engagement with our clients, followers, investors and all social platforms. I enjoy responding to shareholder inquiries, and the demand for engagement and discussion by investors has grown significantly. Engaging with Agoracom followers is an invaluable tool given our anticipated developments and I look forward to posting my comments and interactions with shareholders.”

The Empower Clinics Verified Forum can be found at https://agoracom.com/ir/EmpowerClinics/forums/discussion

About Empower

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients and provide long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Dustin Klein
Director
[email protected]
720-352-1398

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

ThreeD Capital $IDK.ca $IDKFF To Disclose Monthly Net Asset Value Per Share $PKK.ca $PKKFF $MTRX.ca $RACMF

Posted by AGORACOM-JC at 7:27 AM on Monday, December 14th, 2020
IDK-square-for-blog
  • Announces that it will begin to publicly disclose unaudited net asset value per share on a monthly basis, commencing with the January 31, 2021 period.
  • This expands on ThreeD’s established practice of releasing NAV on a quarterly basis and reflect our response to shareholder interest in receiving NAV information more frequently.

TORONTO, Dec. 14, 2020 – ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQB:IDKFF) announces that it will begin to publicly disclose unaudited net asset value per share (“NAV”) on a monthly basis, commencing with the January 31, 2021 period. This expands on ThreeD’s established practice of releasing NAV on a quarterly basis and reflect our response to shareholder interest in receiving NAV information more frequently.

Monthly NAV will be disclosed by the Company in a press release and be available on the Company’s website approximately 15 days after month-end. NAV will be calculated based on unaudited month-end financial information.

NAV is a non-GAAP measure calculated as the value of total assets less the value of total liabilities divided by total number of common shares outstanding, as at a specific date. The term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies.

“ThreeD believes that providing monthly NAV updates, will be beneficial to our shareholders by providing information that is useful to understanding our performance”, states Sheldon Inwentash, Chairman and CEO, “This measure will help provide a benchmark to evaluate our business relative to that of our peers”.

About ThreeD Capital Inc.

ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors.  ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
[email protected]
Phone: 416-941-8900 ext 106

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to timing and content of future disclosures of the NAV of the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur including, without limitation, risks relating to the timing and content of future public disclosures by the Company or related to the fact that the term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

VIDEO – Datametrex $DM.ca $DTMXF Discusses Record Q3 and YTD Results, Looks Forward To 2021 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:26 PM on Thursday, December 10th, 2020
Webinar logo

Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter

Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.